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Arachidonoyl ethanolamide (AEA) induces apoptosis in mouse tumorigenic keratinocytes  
(JWF-2 cells). Our previous data show that AEA is metabolized by COX-2 to pro-apoptotic J-
series prostaglandins. COX-2 is an enzyme that is abundant in tumor cells but not in the normal 
epithelial cells surrounding the tumor.  Thus, the pro-apoptotic J-series prostaglandins should be 
selectively synthesized in AEA-exposed tumor cells with elevated COX-2 expression. As such, 
AEA could be developed as a topical agent to treat non-melanoma skin cancer. The main goal of 
this project is to identify the specific J-series prostaglandins that are produced as a result of the 
metabolism of AEA by COX-2 using mass spectrometry. (ELISA analysis can detect J-series 
family prostaglandins but cannot distinguish between the individual J-series isoforms). 
Exogenous J-series prostaglandins were added to fresh cell culture medium, and the 
prostaglandins were extracted using solid phase extraction. Concentrated samples were then 
subjected to Liquid Chromatography/Electrospray Ionization /Mass Spectrometry (LC-ESI-MS) 
in negative mode for identification of J-series prostaglandin isoforms.  Our data show good 
recovery of extracted species and acceptable resolution of these chemically similar standards. 
The culture medium from AEA- and ethanol-treated was extracted using the validated extraction 
protocol and analyzed using the method developed with LC-ESI-MS. The mass spectrum of the 
culture medium obtained from AEA-treated, extracted and concentrated cell culture media 
clearly shows peaks at m/z ratio identified as the parent ion peak (M-H)¯ of  ethanolamide 
conjugates of the J-series prostaglandins. The identification of the ethanolamide conjugates was 
confirmed by performing tandem mass spectrometry. It was also observed that with increased 
AEA concentration, the mass spectral intensity of the ethanolamide conjugates of J-series 
prostaglandins increased. The effect of a COX-2 inhibitor and the antioxidant N-acetyl 
cysteine(NAC), on the production of ethanolamide conjugates of J-series was also studied. The 
identification of the cytotoxic ethanolamide conjugates of J-series prostaglandins as the 
metabolites of AEA synthesized in tumor cells help us to determine the mechanism by which 
AEA induces apoptosis. 
 
 
 
 
 
 
 
 
  
 
 
  Figure 1 Structure of PG-J2 ethanolamide (Exact mass 377.2) 
 
 
 
 
 
 
              Figure 2 The LC-ESI-MS spectrum of AEA treated sample in negative ion mode 
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Chapter 1: Introduction 
 
Cancer is uncontrollable growth of abnormal cells in the body1. Besides growing 
uncontrollably these cells also invade the surrounding tissues which actually make them 
cancerous2. The cells become cancerous due to DNA damage which can be caused by several 
factors such as environmental carcinogens, DNA replication errors by normal cells or by 
inheritance2. Any organ or tissue can develop cancer such as skin, lung, breast or nervous tissue1. 
1.1 Skin Cancer 
Skin cancer is the most common cancer in United States3. The incidence of skin cancer is 
reported to be higher than the incidence of all other cancers combined including lung, breast, 
colon and prostate3. More than two million cases of skin cancer are diagnosed every year3. 
1.1.1 Types of Skin Cancer 
Skin cancers are classified based on the type of skin cells they affect. The cancer 
occurring in melanocytes is referred to as melanoma skin cancer and the cancers occurring in 
basal keratinocytes and squamous keratinocytes is referred to as non-melanoma skin cancers.  
1.1.2 Causes, Signs and Symptoms of Skin Cancer 
There are several factors which are found to have the potential to induce skin cancer4: 
a) Excessive exposure to UV-radiation while outdoors 
b) Excessive exposure to artificial UV-radiation in indoor tanning industries 
c) Declining stratospheric ozone layer protection 
d) Aging 
e) Chemicals such as arsenic 
f) Viruses such as human papilloma virus 
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Skin cancers occur mostly in the sun exposed areas such as upper arms legs, face, nose 
etc. Like many other cancers, skin cancers also start as precancerous lesions which have potential 
to develop into cancers over time5. The appearance of the tumor varies depending upon the type 
of skin cancer. A basal cell carcinoma appears as waxy or pearly bump with visible blood vessels 
whereas a squamous cell carcinoma appears as a scaly or crusty reddish nodule5. 
1.1.3 Non Melanoma Skin Cancer (NMSC) 
NMSC is not only the most common form of skin cancer but also it is also the most 
common human malignancy4. In the United States alone, every year more than 3.5 million new 
tumors are identified in more than 2 million people3 every year. It was reported that about 90% 
of non-melanoma skin cancers are caused due to exposure to UV-radiation from the sun3. 
Between 1992 and 2006, treatment for NMSC has increased 77 percent3. 
1.2 Cannabinoids as Chemotherapeutic agents 
Cannabinoids are the molecules which interact with the cannabinoid receptors and 
produce “tetrad effects” such as hypomotility, hypothermia, analgesia and catalepsy6. They 
possess certain therapeutic properties that are used to mitigate symptoms such as nausea and 
vomiting in cancer patients and neuropathic pain in individuals with multiple sclerosis7. They are 
potential anticancer agents found to suppress tumor growth in various cultured cells and animal 
models7. They can be broadly classified into phytocannabinoids, endocannabinoids and synthetic 
cannabinoids 6,7. 
1.2.1 Phytocannabinoids 
Phytocannabinoids are the chemically active components derived from the plant 
Cannabis sativa (marijuana)7. Several physiological and pathological effects of cannabinoids 
such as the reduction of pain or inflammation were identified for the phytocannabinoid  
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tetrahydrocannabinol (∆9 THC)6.  Cannabidiol (CBD) and cannabinol (CBN) are examples of 
other phytocannabinoids. 
 
Figure 1.2.1   Structure of∆9 Tetrahydrocannabinol(∆9 THC). 
1.2.2 Synthetic cannabinoids 
Synthetic cannabinoids are the chemically synthesized compounds which mimic the 
effects of the phytocannabinoids6 . The examples of synthetic cannabinoids are WIN-55,222-2, 
AM-94 and JWH-200. 
 
Figure 1.2.2 Structure of JWH-018. 
1.2.3 Endocannabinoids 
Endocannabinoids are produced by mammalian cells and also found to mimic the effects 
of phytocannabinoids. Arachidonoyl ethanolamide, also called anandamide, was the first 
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endocannabinoid discovered7. Endocannabinoids play a major role in the central nervous system 
and are also involved in regulation of immunity, cell growth and inflammation8.Other examples 
are 2-arachidonoyl glycerol (2-AG) and oleoyl ethanolamide(OEA). 
 
HO
H
N
O
 
Fig. 1.2.3 Structure of oleoyl ethanolamide(OEA). 
 
1.3 Arachidonoyl ethanolamide 
 Arachidonoyl ethanolamide (AEA) is an N-acyl ethanolamide of arachidonic acid 
(Fig.1.3.1). AEA controls various cellular responses such as cell proliferation, growth arrest, cell 
death and inflammation8. This endocannabinoid is also found to exert cytotoxic effects in many 
types of tumor cell lines including breast, thyroid and skin9, 10. 
 
Figure 1.3 Structure of Arachidonoyl ethanolamide(AEA). 
1.3.1 Selectivity and Cytotoxicity of AEA 
 In the previous studies conducted by Van Dross, et al, AEA was found to inhibit the 
growth of skin tumor cells by inducing apoptosis11. It was also reported that AEA was selectively 
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metabolized to cytotoxic J-series prostaglandins in skin tumor but not in normal keratinocytes11.  
The mechanism of its cytotoxicity is not very well understood.  On the other hand, the selectivity 
of AEA towards the tumor cells may be explained by the fact that the COX-2, which plays a key 
role in the metabolism of AEA, is more abundant in tumor cells than the surrounding normal 
skin cells. 
1.3.2 Metabolism of AEA to J-series Prostaglandins 
 Van Dross, et al, have reported that AEA-induced apoptosis in the skin tumor cells is 
mediated by the production of J-series prostaglandins6.  We hypothesize that AEA is metabolized 
to J-series prostaglandins through one of two possible pathways (Figure 1.3.2).  Pathway A is a 
well-established pathway in normal cells in which AEA is metabolized to arachidonic acid (AA) 
and ethanolamide (EA) in the presence of the enzyme fatty acid amide hydrolase (FAAH). 
Arachidonic acid in turn is metabolized in a series of reactions to J-series prostaglandins. 
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Figure 1.3.2 Metabolic pathway of the conversion of AEA to J-series prostaglandins (pathway 
A) or J-series ethanolamide conjugates (pathway B).  Question marks represent data that is not 
published in the literature. 
 Various studies have reported that as shown in pathway B, AEA is directly metabolized 
by COX-2 to ethanolamide prostaglandins of E-, F- and D-series13, 14. The subsequent 
metabolism of D-series ethanolamide prostaglandins to J-series ethanolamide prostaglandins has 
not been reported in the literature to date. Our main goal is to identify the chemical nature and 
the type of J-series prostaglandin/s produced by the skin tumor cells when treated with AEA 
using LC-ESI-MS.  Although ELISA was used to quantify the J-series prostaglandins by Van 
Dross, et al, identification of the specific classes of molecules was not possible with ELISA. 
The type of tumor cells being studied is the squamous cell carcinoma cell line which is 
the non-melanoma type of skin cancer cell line. Research indicates that AEA has the potential to 
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be developed as topical chemotherapeutic agent to treat non-melanoma skin cancer cells because 
of its selectivity and cytotoxicity to the skin tumor cells6.  Our research is focused towards the 
better understanding the metabolism of AEA which is critical for further research and 
development of AEA as a chemotherapeutic drug. 
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Chapter 2: Techniques and Instrumentation 
2.1 Techniques 
 Besides LC-ESI-MS, the other important bioanalytical techniques used either for the 
validation of the protocols or for monitoring the cellular response to the drug treatment were 
ELISA and Western blot. ELISA was used for the validation of the extraction protocol discussed 
in detail in chapter 4.4.2. The AEA-treated cells were subjected to Western blot analysis to 
monitor cell death.  
2.2.1 ELISA 
 ELISA is used for the detection of specific antibodies, soluble antigens or cell surface 
antigens15. The different types of ELISA protocols used are indirect, direct competitive, antibody 
sandwich, double antibody sandwich, direct cellular and indirect cellular15. Although the most 
common applications of all the ELISA protocols listed are either antigen or antibody screening, 
some of them are also used to measure cellular antigen expression. 
 We have used a 15-deoxy ∆12,14 PG-J2 Enzyme Immunoassay Kit (Assay Designs, Ann 
Arbor, MI) to quantify the amount of J-series prostaglandins in the solvent washes and the eluate 
collected at different steps in the extraction process. This kit is a competitive immunoassay used 
for quantitative determination of 15-deoxy ∆12, 14 PG-J2 in the biological sample. As discussed 
earlier in Chapter 1, this kit is not specific for just the 15-deoxy ∆12, 14 PG-J2 because it is shown 
to have some cross-reactivity with the other types of J-series prostaglandins. Also, this kit does 
not differentiate between the 15-deoxy ∆12, 14 PG-J2 and the ethanolamide conjugates of the 
same. However, irrespective of the lack of selectivity, this kit provided good correlation between 
the increasing dose of AEA and the production of J-series prostaglandins quantified by Van 
Dross, et al6. 
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 The principle involved in the quantification is the competitive binding of the 15-deoxy-
∆12, 14PG-J2 antibody to 15-deoxy ∆12, 14 PG-J2 in the sample or the 15-deoxy-∆12,14PG-J2  
attached to an alkaline phosphatase buffer. The ELISA plate coated with the goat antibody is 
incubated either with a 15-deoxy-∆12, 14 PG-J2 standard or the sample containing 15-deoxy-∆12,14 
PG-J2 along with the15-deoxy-∆12,14PG-J2  attached to an alkaline phosphatase and the 15-deoxy 
 ∆12, 14PG-J2 antibody for 2hours on plate shaker at  ~500 rpm. During this time, the analyte and 
the analyte-enzyme complex compete for binding with the primary antibody which in turn bind 
to the goat antibody. The unbound analyte and the analyte-enzyme complex are washed away 
using a wash buffer and the substrate p-nitrophenyl phosphate in buffer is added and incubated 
for 3 hours. After incubation the enzyme reaction is stopped by using a stop buffer and the 
yellow colour developed due to the metabolite that is formed due to reaction between the 
phosphatase enzyme and the p-nitrophenyl phosphate substrate is read on a microplate 
reader(UV-vis spectrophotometer) at 405 nm.  Figure 2.2.1 describes a representative ELISA 
measurement of 15-deoxy ∆12, 14 PG-J2 using 15-deoxy ∆12, 14 PG-J2 phosphatase conjugate.   
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Figure 2.1.1  A representative ELISA measurement of 15-deoxy ∆12, 14 PG-J2  using 15-deoxy 
∆12,14 PG-J2 -phosphatase conjugate. (Adapted from Current Protocols in Immunology(1999) 
7.33.2)15. 
2.1.2 Western Blot Analysis 
Western blot is proteomic technique used for the detection of proteins in cells, tissue 
lysates or extracts. It can also be used for the determining the size of the protein, its relative 
abundance and also phosphorylation status. The proteins are extracted from the cell, quantified 
and then loaded on to the gel for purification. The proteins are separated on the gel based on their 
size by electrophoresis.  After separation, the proteins from the gel are transferred to a membrane 
followed by blotting with the specific antibody and signal detection as illustrated in the 
 A 
 C 
 B 
 D 
goat  polyclonal 
antibody 
15-deoxy ∆12,14 PG-J2 
15-deoxy ∆12,14 PG-J2-
phosphatase 
15-deoxy ∆12,14 PG-J2 
polyclonal antibody 
 
 
11 
 
Figure2.1.2. The brief protocol used to analyze the form of the protein poly (ADP-ribose), 
abbreviated as PARP, in AEA-treated JWF-2 cells is discussed in chapter 3. 
 
 
 
 
 
Figure 2.1.2 An illustration of Western blot analysis. A) Extraction of proteins from the cells 
attached to the plate. B) Gel electrophoresis followed by membrane transfer. C) Membrane 
blotting and signal detection. (adapted from Molecular station, Western blot) 
 
 
 
     
 
C 
A 
B 
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2.2 Instrumentation 
  LC-ESI-MS was performed on a Waters Acquity UPLC system coupled with a 
Micromass QToF mass spectrometer. A schematic of the instrument is illustrated in Figure 2.2. 
The prostaglandins are chromatographically resolved on an Acquity UPLC using a BEH 
(Ethylene Bridged Hybrid) column with C8 particles (particle diameter 1.7µM).  The column has 
a 2.1 mm inner diameter and 100mm length (Waters, Milford, MA). The mobile phase consisted 
of 90/10 water/acetonitrile (solvent A) and 100% acetonitrile (solvent B). UV grade Acetonitrile 
was filtered through a 0.1 micron filter by the manufacturer (Honeywell B&J, Muskegon, MI) 
and is 99.9% pure. Solvent A was prepared by mixing ultrapure deionized water (18MΩ-cm) and 
acetonitrile. The gradient started with solvent A decreasing from 65% to 50% A at 5%/minute, 
and then from 50% to 35% A at 7.5%/minute. A constant flow rate of 0.4 mL/minute was used 
and the injection volume was 20 µL.  
 
Figure 2.2 A schematic representation of the LC-ESI-MS instrument 
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2.2.1 Electrospray Ionization source  
 The mass spectrometer, equipped with an electrospray ionization source, was used for 
ESI-MS and ESI-MS-MS. The instrument was operated in negative ion mode with the capillary 
voltage set at 3.2kV, which creates a strong electric field in which ions are formed.  Nitrogen gas 
promotes the formation of an aerosol with the charged particles. The sampling cone and the 
extraction cone shown in the schematic of the instrument (Figure 2.2) act to steer the ions to the 
mass spectrometer and aid in “skimming” the remaining solvent from the electrospray plume. 
The potential difference at the skimmers controls the extent of fragmentation, referred to as in-
source dissociation. The essential parameters optimized for an LC-ESI-MS analysis are listed in 
Table 2.2. The desolvation and source temperatures for LC-ESI-MS analysis are much higher 
than for direct ESI-MS analysis because the flow rate is higher.  Also the flow rate of cone gas is 
maintained at 10 L/hour during an LC-MS analysis to reduce the comparatively higher volume of 
sample entering into the mass spectrometer. The eluate from the UPLC is directed into the 
electrospray ionization source. When the eluate enters the steel nebulizer of the ESI source, a 
Taylor cone is formed due to high potential difference between the ESI needle and its counter 
electrode .The ions are formed at the tip of the Taylor cone16 and enter as gas phase ions into the 
Q-ToF. 
Table 2.2 Settings for LC-ESI-MS analysis 
Parameter LC-MS ESI-MS 
Desolvation Temperature (ºC) 120 80 
Source Temperature (ºC) 275 120 
Cone gas (L/hr) 10 0 
Desolvation gas (L/hr) 500 500 
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2.2.2. Quadrupole-Time of Flight mass analyzer 
 The ions in the gas phase are directed towards the Q-ToF mass analyzer. During MS 
analysis the quadrupole focuses all the ions towards the ToF analyzer. In MS/MS analysis, the 
quadrupole is operated in a mass filter mode to transmit only the parent ion of interest17. The 
selected parent ion is accelerated to energy of 20-40 eV before it enters the collision cell and 
undergoes collision-induced dissociation by colliding with the neutral gas molecules (argon). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
15 
 
Chapter 3: Experimental 
3.1 Experimental Design 
 The entire experimental analysis can be summarized under two categories:  extracellular 
and intracellular analysis.  After treating the JWF-2 cells with AEA, the media is extracted, 
concentrated and analyzed using LC-ESI-MS.  The treated cells containing the protein markers 
for apoptosis are analyzed using Western blot technique. 
3.2 Cell Culture 
 The type of cells cultured is the murine squamous cell carcinoma cell lines called the 
JWF2 cells (Dr.Susan Fischer, University of Texas; MD Anderson Cancer Center, Smithfield 
TX).  The cells are cultured in Eagle’s Minimal Essential Media (SMEM) (US Biological, 
Marblehead, MA). The cells are split when they are close to being 100% confluent and have no 
more space to grow.  If they are not confluent enough to split, the cells are fed with media until 
they are ready to split.  Cells need to be regularly split or fed on every alternate day or within a 
maximum gap of two days, again depending on the confluency of cells. The following are the 
detailed protocols for cell splitting, cell feeding and preparation of the media for the cell culture. 
Cell splitting protocol 
The SMEM media containing heat inactivated fetal bovine serum (FBS), penicillin 
(100mg/mL), streptomycin (100mg/mL), non essential amino acids and glutamine and trypsin 
are warmed to 37ºC prior to the experiment.  Media is removed from a 75cm2 flask, washed 
twice with 10 mL of phosphate buffer each and incubated with 2 mL of warmed trypsin in a CO2 
incubator maintained at 37ºC. Trypsin is removed from the flask after a minute followed by 
incubation for another 4 minutes. The residual trypsin acts on the cells and helps them detach 
from the surface. After incubation, the bottom of the flask is tapped to dislodge the cells from the 
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flask.  Approximately 10 mL of the warmed SMEM media is added to each flask containing 
cells, transferred into a sterile centrifuge tube (15/50mL) tube and centrifuged for 5 minutes at 
1200 rpm.  Media is removed and the appropriate amount of fresh SMEM media is added 
depending on the pellet size (2-7 mL).  The resulting cell suspension is mixed well to get a 
uniform cell suspension. The cell suspension is distributed into new set of 75cm2 flasks followed 
by incubation.  For each experiment, cells are plated in 100mm dishes at a density of 75,000 
cells/mL. To count the cells, 10μL of the cell suspension is added to 10μL of trypan blue dye, 
and cells are counted using a hemocytometer and microscope. 
3.3 Cell treatment 
 The cells are plated 48 hours prior to the day of the experiment to achieve 85-90% 
confluency on cells.  The cells are treated using SMEM media containing penicillin 
(100mg/mL), streptomycin (100mg/mL), non essential amino acids, glutamine and calcium 
chloride. As this media does not contain FBS, it is also called serum free SMEM media (SF-
SMEM).  The cell treatment slightly varies depending upon the experiment. 
3.3.1 Cell treatment with AEA and ethanol as control 
The concentration of AEA used to treat the cells was 10µM, 20µM or 30µM and was 
prepared by adding the appropriate amount of AEA stock to SF-SMEM media (warmed to 37ºC 
prior to the experiment).  The control treatment is prepared by adding the same volume of 
ethanol (AEA solvent) as that of AEA stock added to the SF-SMEM media.  Media, which was 
present on the cells for 48 hours (spent media), is removed from the culture dishes and 10 mL of 
either AEA or ethanol containing SF-SMEM is added to each plate. The plates are then labeled 
and incubated for approximately 5 hours in the CO2 incubator. After the treatment, the media is 
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collected into clean 15 mL centrifuge tubes and stored at -80ºC until extraction. The plates which 
contain attached cells are washed twice with 10 mL of ice cold PBS and also stored at -80ºC. 
3.3.2 Cell pretreatment with N-acetyl cysteine followed by treatment with AEA 
A stock solution of 1M N-acetyl cysteine (NAC) was prepared and filter sterilized.  A 
final concentration of 75 mM NAC is prepared by adding 3 mL of the 1M stock solution to 37 
mL of SF-SMEM media (warmed to 37ºC prior to the experiment).  Adding NAC to the media 
decreases the pН of the media which is restored to pH 7 with 1N NaOH solution.  Spent media is 
removed from the cells and then cells are pre-treated for 2 hours with 75 mM NAC or an equal 
volume of water (solvent for NAC) prepared in SF-SMEM media.  After 2 hours, 20 µM AEA or 
an equivalent volume of ethanol is added to the NAC-containing media used for the 
pretreatment. The media is then added back to the cells, and incubated for 5 hours in the CO2 
incubator. The treatments are summarized as follows: 
a) Water (pretreatment) and Ethanol (treatment)  
b) NAC (pretreatment) and Ethanol (treatment) 
c) Water (pretreatment) and AEA (treatment) 
d) NAC(pretreatment) and AEA (treatment) 
After the treatment the media is collected into fresh 15 mL centrifuge tubes and stored at 
-80ºC until extraction. The plates containing the treated and attached cells are washed twice with 
10 mL ice cold PBS and also stored at -80ºC. 
3.3.3 Cell pretreatment with COX-2 inhibitor (NS-398) followed by treatment with AEA 
Spent media is removed from the cells and the cells are pretreated with either 25 µM or 
50 µM of NS-398 or with DMSO (NS-398 solvent) as control for 45 minutes prepared similarly 
as discussed in earlier sections (3.3.2 and 3.3.3).  After 45 minutes, 20µM AEA or an equivalent 
 
 
18 
 
volume of ethanol is added to the same media used for the pretreatment.  The media is then 
added back to the cells, and cells are incubated for 5 hours in the CO2 incubator.  The treatments 
are summarized as follows: 
a. DMSO pretreatment and Ethanol treatment 
b. NS-398 (25uM) pretreatment and Ethanol treatment 
c. NS-398 (50uM) pretreatment and Ethanol treatment 
d. DMSO pretreatment  and AEA treatment 
e. NS-398 (25uM) pretreatment and AEA treatment 
f. NS-398 (50uM) pretreatment and AEA treatment 
After the treatment the media is collected into fresh 15 mL centrifuge tubes and stored at 
-80ºC until extraction. The plates containing the treated and attached cells are washed twice with 
10 mL of ice cold PBS and also stored at -80ºC. 
3.4 Extracellular analysis 
 After the cell treatment, the media is extracted and then concentrated before LC-ESI-MS 
analysis. Solid phase extraction is used for isolating the prostaglandin molecules from the media.  
The solid phase C18 columns are fixed on to the extraction apparatus and are operated under 
vacuum.  Prostaglandins tend to stick to plastic surfaces, so only glass pipettes are used 
throughout the extraction procedure, and the final eluates are collected in glass vials. 
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3.4.1.1 Extraction of prostaglandin standards from SF-SMEM media  
Prostaglandins (PG-J2, 15-deoxy ∆12,14 PG-J2, and 12 PG-J2)  were dissolved in ethyl 
acetate and purchased from Cayman Chemical (Boston, MA). Samples were evaporated to 
dryness with nitrogen gas and reconstituted in ethanol immediately before use.  SF-SMEM 
media is warmed to 37˚C prior to the experiment and PG-J2, 15-deoxy ∆12,14 PG-J2 and 12 PG-J2 
are added to the 1 mL of the either fresh or spent SF-SMEM media in a 1mL centrifuge tube to a 
final concentration of 3, 6 and 12 µM respectively.  The same volume of ethanol as that of the 
total volume of all the prostaglandins is added to the media and also extracted similarly as a 
control.  The media spiked with prostaglandins or ethanol is acidified by adding 2M HCl to 
adjust the pН to approximately 3.5. The media is then placed on ice for 15 minutes followed by 
centrifugation at a maximum speed for 2 minutes to remove any precipitates.  The media is then 
transferred into a fresh tube for extraction. Solid phase C18 columns (GRACE, Grace Davidson 
Discovery Science, Deerfield, IL) of 1.5 mL capacity are fixed on to the extraction apparatus. 
The columns are equilibrated with 1 mL of 100% acetonitrile to condition the column and flush 
out the previously adsorbed species. The columns are then washed with 1mL of ultrapure 
deionized water and the supernatant is applied to the columns. The columns are washed with 1 
mL of ultrapure deionized water followed by solvent wash with 1 mL each of 15% acetonitrile 
and hexane. The prostaglandins are finally eluted in 1 mL of 100% acetonitrile, transferred into a 
glass vial and stored at -80˚C before evaporation and reconstitution. 
3.4.1.2 Protocol for extraction of prostaglandins from the media after the cell treatment 
Thawed media is acidified with 2M HCl to adjust the pН to approximately 3.5, placed on 
ice for 15 minutes, and centrifuged at a maximum speed for 2 minutes to remove any 
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precipitates.  The supernatant is then transferred into a fresh centrifuge tube for extraction, 
following the same extraction steps detailed in Section 3.4.1.1.   
3.4.2 Evaporation and Reconstitution 
 The extracted media is evaporated to dryness under a stream of nitrogen gas followed by 
reconstitution in 0.010 mL acetonitrile.  More dilute analyte solutions (prepared with larger 
volumes of acetonitrile) were not detectable at high signal-to-noise ratios with mass 
spectrometry.    
3.5 Intracellular analysis  
 In their previous studies, Van Dross et al have demonstrated by Western blot analysis that 
AEA induces cell death by apoptosis in skin tumor cells. The following are the steps involved in 
the Western blot analysis of the AEA treated JWF-2 cells.  
1. BCA assay(bicinchoninic acid assay) 
2. Western Blot-gel electrophoresis 
3. Transfer of proteins to polyvinylidene diflouride(PVDF) membrane 
4. Membrane blotting 
5. Signal detection 
3.5.1 BCA assay 
Protease inhibitors solution is prepared by adding1μL each of Aprotin, Pepstatin, and 
DDT; 2μL each of Sodium Vanadate and Okadaic acid; 5μL of Leupeptin; 8 μL sodium fluoride; 
and 10 μL Phenylmethylsulfonyl fluoride (PMSF) in 1ml of Tissue lysis buffer solution (TLB). 
This inhibitors prevent the lysis of the proteins present in the cell by proteases and phosphatases. 
The cell plates stored at -80˚C are left to thaw on an ice bed. Approximately 100 μL of TLB 
buffer containing the protease inhibitors is added to the plates and the entire surface of the plate 
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is scrapped with a cell scraper. The mixture is collected from one end of the plate and transferred 
to a labeled microfuge tube on ice. The cell scraper is cleaned in 70% ethanol between each 
sample collection. The samples are vortexed for 10 seconds each after each plate has been 
scrapped. Alternatively, cell lysate can be taken up and down with a needle and syringe (18 
gauge) 8 times each.  The samples are centrifuged at 12,000 rpm for 10 minutes at 4ºC and the 
supernatant is transferred into a clean labeled microfuge tube.  An aliquot of each sample is 
transferred into a microfuge tube for protein concentration determination.  For this cell line, 6 uL 
of the cell lysate is added into tubes containing 18 μL of water.  The protein concentration in 
each sample is measured using a BCA reagent kit.  
A 96 well plate is loaded with 10 μL of BSA standards in duplicates with concentrations 
of 0, 125, 250, 500, 1000, and 2000 (µg/mL). Similarly, 10 μL of the samples are loaded in 
duplicates.  Exactly 200 μL of the BCA solution, prepared by adding reagents B and A (1:50 
ratio), is added to each of the wells loaded with the BCA standards or the samples.  The plate is 
incubated for 30 minutes at 37˚C and is read using a microplate reader (Biotek, Winooski, VT). 
3.5.2 Western Blot-Gel electrophoresis 
Samples are prepared in centrifuge tubes based on the BCA assay.  Each sample is 
prepared in order to have the same amount of protein (~30 μg) loaded onto each well of an SDS-
PAGE gel( sodium dodecyl sulfate polyacrylamide gel electrophoresis).  A fixed amount of dye 
and water are also added to each sample to make up all the samples to the same final volume.  
The samples are heated for 5 minutes and then immediately loaded on the gel.The gel is run and 
at 56 mA until the blue dye front disappears from the gel. 
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3.5.3 Transfer of protein to PVDF membrane 
The PVDF membrane is washed once in methanol and twice in water. The membrane and 
the gel are incubated in the transfer buffer for 15 minutes on a shaking rocker. The apparatus for 
the transfer is set-up and transfer can be conducted at 100V for 100 minutes using a 2 hour buffer 
(72.6g Tris Base, 75g Glycine, 4g SDS, 800 ml methanol- QS to 4L with water) or 20V for 16 
hours at 4˚C using an overnight buffer (9.7g Tris Base, 44.7g Glycine- QS to 4L with water). 
3.5.4 Membrane Blotting 
The membrane is blocked for one hour in TBST (Tris-buffered saline with tween 20) 
containing 5% (w/v) non-fat dry milk (NFDM) on the rocker.  Primary antibody (PARP and 
GAPDH) is added to fresh 5% non-fat dairy milk at a ratio 1:1000 dilution, and membrane is 
incubated in this solution for 3 hours at room temperature or overnight at 4˚C on the rocker. The 
membrane is then washed twice in TBST on the rocker for 5 min each.  Secondary antibody is 
added to the appropriate blocking buffer (5% NFDM) in a 1:10,000 dilution membrane and is 
incubated in this solution for 1 hour at room temperature on the rocker.  The membrane is then 
washed three times in TBST for 5 minutes each followed by one time in TBS (without tween) for 
5 minutes on the rocker 
3.5.5 Signal Detection  
Enhanced chemiluminescence (ECL) Reagent is prepared by mixing 75 μL of reagent 
B(peroxide solution) and 3 mL of reagent A(luminal and enhancer). After the final wash excess 
TBS is blotted off the membrane and then ECL solution is added and incubated for a minute.  
The excess ECL solution is blotted off the membrane and the membrane is placed in the cassette. 
In the dark room, the signal is captured on the X-ray film and then developed. 
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Chapter 4: Analysis of Prostaglandin Standards and Validation of Protocols 
 The largest focus of this study was the development and validation of an LC-ESI-MS 
method for prostaglandins. The possible prostaglandin metabolites were either the J-series 
Prostaglandins which are 12 PG-J2, PG-J2 or 15-deoxy12, 14 PG-J2 or their ethanolamide 
conjugates.  Since the ethanolamide conjugated J-series prostaglandins are not available 
commercially, method development and validation were done using the unmodified J-series 
prostaglandins. 
4.1 ESI-MS analysis of the unmodified J-series prostaglandins 
 Reference mass spectra of the three J-series prostaglandins (12 PG-J2, PG-J2 and 15-
deoxy-12,14 PG-J2) were obtained in negative ion mode ESI.  Table 4.1 lists the m/z ratios of the 
deprotonated molecules and the common product ions of J-series 
  
Table 4.1 Possible mass spectral fingerprints of the J-series prostaglandin ethanolamides 
Molecule m/z (M-H)¯ m/z Fragments of (M-H)¯ 
PG-J2 333.2 315.2,271.2,189.2 
15-deoxy-∆12,14-PG-J
2
 315.2 271.2, 189.2 
∆12-PG-J
2
 333.2 315.2, 271.2, 189.2 
 
prostaglandins calculated using the monoisotopic masses up to one decimal place.  12 PG-J2 and 
PG-J2 are positional isomers, so they have the same m/z ratios. 
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Figure 4.1.1 Structures of the two isomeric J-series Prostaglandins and their exact molar masses. 
Prostaglandin ions fragment easily during transfer in the mass spectrometer, giving good 
signal intensity of the deprotonated molecule and the product ions. A mass spectrum showing 
significant product ions can be more informative than a spectrum showing just an intact ion. As 
seen in Figure 4.1.2, ESI-MS of 12 PG-J2 and PG-J2 yield mass spectra with the same 
deprotonated molecule and product ion peaks formed from in-source dissociation.  Additionally, 
a significant number of peaks are observed in the mass spectra that are not related to the 
prostaglandin ions.  They are a polymeric distribution of ions (separated by 14 m/z units) that are 
likely introduced from the solvents used.   
4.2 ESI-MS-MS analysis of the unmodified J-series prostaglandins 
ESI-MS-MS allows us to confirm the relationship among product and parent ions and 
remove the interfering signal from the solvent contamination.  In an MS-MS experiment, a 
parent ion of interest, here the deprotonated molecule, is isolated and dissociated, resulting in the 
spectra shown in Figure 4.2.1. A peak at m/z 271 was observed in all MS/MS spectra.  In Figure 
4.2.1 (A) and (B), product ion peaks at m/z 189, 233, and 315 also were observed.  Product ion 
structures are shown in Figure 4.2.2.18 These m/z values can be used as markers for 
prostaglandins in our LC-ESI-MS spectra. 
The isomeric prostaglandins were subjected to further ESI-MS-MS analysis at higher 
collision energy, expecting that these would dissociate differently resulting in the production of 
PG‐J2 
Exact mass 334.2 
Δ12‐PG‐J2 
Exact mass 334.2 
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unique product ions. However, the isomers were found to have identical product ions even at 
higher collision energies and no unique product ions were identified. 
 
Figure 4.1.2 Negative-mode ESI-MS analysis of A) PG-J2  B) 12 PG-J2  and C) 15-deoxy12,14 
PG- 
A 
B 
C 
(M-H)¯ 
(M-H-H20)¯ 
(M-H-H20-CO2)¯ 
(M-H)¯ 
(M-H-H20)¯ 
(M-H-H20-CO2)¯ 
(M-H)¯ 
(M-H-CO2)¯ 
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Figure 4.2.1 Negative mode ESI-MS-MS analysis of A) PG-J2  B) 12 PG-J2 and 
A 
B 
C 
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C) 15-deoxy-12,14 PG-J2 
 
Figure 4.2.2 Structures of product ions formed from PG-J218 
 
4.3 Method development with LC-ESI-MS for analysis of the prostaglandins 
 LC-ESI-MS can be used to first separate the prostaglandin molecules and then detect 
them using the mass spectrometer.  LC removes unwanted biological material from entering the 
mass spectrometer, as well.   
A sample containing a mixture of all three prostaglandin standards was analyzed.  Figure 
4.3.1 shows the most effective chromatographic separation of the isomers identified based on the 
m/z values detected and the ratios of concentrations of standards used to prepare the mixture.  
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However, resolution of the two isomers PG-J2 and Δ12 PG-J2 has been achieved only in this 
experiment; in most other experiments attempted, the isomers tend to co-elute because of their 
very close structural similarity compared to 15-deoxy-Δ12,14 PG-J2.   
 
 
Figure 4.3.1 Demonstration of an LC separation of a mixture of J-series prostaglandins 
 
A variety of reversed-phase gradient elution programs were developed in an attempt to 
efficiently separate the prostaglandins before introduction into the mass spectrometer. No 
separation of the two isomers was achieved; thus, the gradient elution that produced the sharpest 
peaks was chosen, where the mobile phase solvent was decreased from 65% to 50% A at 
5%/minute, and then from 50% to 35% A at 7.5%/minute.   
 The LC-ESI-MS chromatogram of the mixture of the J-series prostaglandins shown in 
Figure 4.3.2A demonstrates separation of J-series prostaglandins typically achieved with the 
optimized gradient. It was observed that PG-J2 and 12 PG-J2 co-eluted first followed by the 
elution of 15-deoxy ∆12, 14 PG-J2. The mass spectra scanned across the peak eluting around 0.5-
0.8 minutes did not have any prostaglandin related peaks. This chromatographic signal may be 
Δ 12PG-J2 
PG-J2 15 -deoxy Δ 12,14 PG-J2 PG-J2 15 -deoxy Δ 12,14 PG-J2 
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attributed to either the sample matrix or the carryover from the column. The latter peaks were 
identified as the prostaglandin related based on the mass spectra scanned across the peaks. Mass 
spectra summed across the two chromatographic peaks are shown in Figure 4.3.2 (B) and (C).  
This gradient method was used for the validating the extraction technique and for the LC-ESI-
MS analysis of the real-world samples. 
 
 
 
Figure 4.3.2 A) LC-ESI-MS chromatogram of the mixture of the J-series prostaglandins. 
 LC-ESI-MS mass spectra across the peak identified as PG-J2 & ∆12-PG-J2 (B), 
15-deoxy-∆12, 14-PG-J2 (C) 
 
 
 
 
PG-J2 & ∆12-PG-J2 15-deoxy-∆12, 14-PG-J2  
A 
B  C
    (M-H)¯ 
    (M-H-CO2)¯ 
    (M-H)¯     (M-H-H20-CO2)¯ 
    (M-H-H2O)¯ 
    (M-H-Hexanal)¯ 
    (M-H-HexanalCO2)¯ 
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4.4 Validation of the extraction technique 
 The extraction technique developed was validated first by extracting the spiked media 
and analyzing those using LC-ESI-MS. Later the real samples were also used to validate the 
extraction protocol using ELISA.  
4.4.1 Validation of extraction protocol using LC-ESI-MS. 
 The extraction protocol was validated using both the spiked fresh media and spiked spent 
media. The fresh media is the media that has not been exposed to the cells, whereas the spent 
media is exposed to cells for 48 hours. By extracting the spiked fresh media, we initially wanted 
to check the efficiency of our extraction protocol. Later, the same protocol was used for 
validation with the spiked spent media to check if cells release anything into the media which 
ionize to give the same m/z ratio as that of the prostaglandin molecules. The fresh or the spent 
media was spiked with the known concentration of the unmodified J-series prostaglandins and 
extracted using the protocol discussed in chapter 3.4.1.  After the extraction, the samples were 
subjected to LC-ESI-MS. 
The LC-ESI-MS chromatograms shown in Figure 4.4.1 A and B demonstrate that the 
prostaglandins added to the media before extraction were recovered.. The mass spectral 
intensities of the prostaglandins were in reasonable agreement with the intensities obtained 
during an LC-ESI-MS analysis of the same mixture in acetonitrile, indicating the extraction 
protocol developed was efficient. Similar extraction efficiency was also obtained with the spiked 
spent media. Hence the extraction protocol was validated with the unmodified J-series 
prostaglandins using LC-ESI-MS. 
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Figure 4.4.1 LC-ESI-MS chromatogram of the A) spiked fresh media after extraction 
 B) spiked spent media after extraction 
4.4.2 Validation of extraction protocol using ELISA. 
  If AEA metabolizes to ethanolamide conjugates of the J-series prostaglandins, the same 
extraction protocol might still need to be validated as the ethanolamides are structurally different 
from the unmodified ones. But, irrespective of the type of prostaglandins produced, Van Dross, 
et al6, were able to quantify the J-series prostaglandins using ELISA. They have used the media 
to quantify the prostaglandins which was used to treat the cells with AEA.  Similarly, we 
monitored all fractions during SPE with ELISA. The results from ELISA indicated that the final 
PG-J2 & ∆12-PG-J2
15-deoxy-∆12, 14-PG-J2  
PG-J2 & ∆12-PG-J2
15-deoxy-∆12, 14-PG-J2  
A 
B 
 
 
32 
 
eluent had a significant amount of prostaglandins and the other washes including the flow 
through from the column did not have any prostaglandins. Thus, prostaglandins were not being 
lost during washings or other extraction steps, and they were being eluted during the final elution 
step of SPE.  The extraction protocol was validated for the prostaglandin metabolites which 
could be either the ethanolamide or the unmodified J-series prostaglandins.  
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Chapter 5: Identification of Prostaglandin-Ethanolamides 
 
5.1 Analysis of AEA-treated cell media by LC-ESI-MS 
 After successful validation of the extraction technique using ELISA, the culture medium 
from the AEA-treated cells was extracted using the validated extraction protocol. Extraction was 
followed by evaporation and reconstitution in acetonitrile. The samples were then analyzed using  
LC-ESI-MS and LC-ESI-MS/MS.  As already stated, because the J-series Prostaglandin-
ethanolamides are not commercially available, the method development with LC-ESI-MS was 
done using unmodified J-series prostaglandin standards.  
  The table below summarizes the possible m/z ratios of the molecular ion (M+EA-H)¯ of 
the ethanolamide conjugates of the J-series prostaglandins. ‘M’ represents the exact molecular 
mass of the J-series prostaglandin and ‘EA’ stands for ethanolamide group. 
 
Table 5.1 Possible Mass spectral fingerprints of the ethanolamide J-series prostaglandins 
Molecule m/z(M+EA-H)¯ 
PG-J2 376.2 
15-deoxy- 
∆12,14-PG-J
2
 
358.2 
∆12-PG-J
2
 376.2 
 
The following are the chromatograms acquired for the control and AEA-treated samples. 
The control here refers to the ethanol-treated cells instead of AEA. Ethanol is the solvent for 
AEA. The purpose of having a control is to check if ethanol, media or anything released from the 
cells into the media in the absence of the AEA ionize to give the  m/z ratio similar to our analyte. 
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Figure 5.1.1 Total ion chromatograms of an LC-ESI-MS analysis of the media of cells treated 
with A) ethanol (control) and B) AEA. 
The chromatograms were then extracted using a data processing tool to obtain an 
extracted ion chromatogram for the m/z ratio of one of the possible ions of the analyte.  This 
process simplifies spectral interpretation by showing the intensity of only one selected m/z ion as 
a function of time.  Extracted ion chromatograms were generated for the m/z values listed in 
Table 5.1, and signal consistent with ethanolamide conjugates of the J-series Prostaglandins was 
obtained at retention times of 0.5-3.0 minutes. Figure 5.1.2 (A) and (B) illustrate this process for 
the ethanol treated and AEA treated media. These are the extracted ion chromatograms, in which 
only the intensity of m/z 358 is plotted as a function of time.   
A 
B 
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Figure 5.1.2 Extracted ion chromatogram of an LC-ESI-MS analysis of the media of cells 
treated with A) ethanol (control) and B) AEA. 
The extracted ion chromatogram of the ethanol-treated media was normalized against the 
signal intensity of the m/z 358 of the AEA treated media. Figure 5.1.2(A) illustrates that all the 
signal intensity of m/z 358 shown in the Figure 5.1.2(B) is associated with the AEA treatment 
and none from the reagents or the cells. Also, the extracted ion chromatogram quickly illustrates 
to the user where to look for more mass spectral fingerprints.  Mass spectra were summed over 
the time range indicated by m/z 358 signal in the extracted ion chromatogram in Figure 5.1.2(A) 
and (B).  In Figure 5.1.3(B), in addition to signal arising from m/z 358, the ethanolamide 
A 
B 
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conjugate of 15-deoxy12,14 PG-J2, m/z 376 is also observed which corresponds to the 
ethanolamide conjugate of either prostaglandin isomer, 12 PG-J2/PG-J2.  
 
Figure 5.1.3 LC-ESI-MS analysis of the media of cells treated with A) ethanol (control) and  
B) AEA.  
The m/z 358 and 376 peaks, corresponding to (M+EA-H)¯ ion of 15-deoxy12,14 PG-J2  
and 12 PG-J2/PG-J2 respectively, were identified only in the mass spectrum of culture medium 
of AEA-treated cells as shown in the Figure 5.1.3(B). Further confirmation was essential to 
confirm the identity of the peaks as ethanolamide conjugates of the J-series prostaglandins. This 
was achieved by subjecting the identified peaks to LC-ESI-MS-MS analysis. As discussed earlier 
A 
B 
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in Chapter 2.2, the MS-MS was performed with collision induced dissociation. The parameter 
that is critical for a MS-MS analysis is the collision energy. Optimizing the collision energy to 
favor reasonable signal intensity of the parent and product ions is very crucial. As very high 
collision energy would cause scattering of the parent ion making its passage unlikely through the 
hexapole collision cell. On other hand very low collision energy would result in little to no 
dissocaition. This depends on the nature of the parent ion and collision gas used.  In a QToF, 
collision energies ranging from 10-40eV were tested, and the collision energy for analyzing the 
ethanolamide conjugates was optimized to 15eV. The parent ions (m/z 376 and 358) were then 
subjected to CID at 15eV and the spectra were scanned across the peak eluting from the LC at 
0.5-3.0 minutes. 
                  
Figure 5.1.4 LC-ESI-MS/MS analysis of the parent ion A) m/z 376 B) m/z 358 identified as the 
ethanolamide conjugates of J-series in AEA treated sample. 
A 
B 
(M+EA-H)¯ (M+EA-H-H20)¯ 
(M-H-H20-CO2)¯ 
(M+EA-H)¯ 
(M-H-CO2)¯ 
(M-H-H20-C2H4CO2)¯ 
(M-H-C2H4CO2)¯ 
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 The CID spectra shown in Figure 5.1.4 (A) of the parent ion peak (m/z 376) shows the 
relevant product ions at m/z 358 [M+EA-H-H2O]¯, 271 [M-H-H2O-CO2]¯ 
and 243 [M-H-H2O-C2H4CO2]¯.  Similarly, the CID spectrum of the parent ion (m/z 358) shows 
the product ion peaks at m/z 271 [M-H-CO2]¯ and 243 [M-H-C2H4CO2]¯. The observed product 
ions were consistent with the fragmentation pattern demonstrated by the J-series prostaglandins 
discussed earlier in chapter 4.2. For example, the product ion at m/z 271 was identified in the 
CID spectrum of the both the parent ions (m/z 376 and 358) which was also previously identified 
as the product ion of the J-series prostaglandins. Hence, the ion corresponding to m/z 376 is 
structurally confirmed as the deprotonated molecule of the ethanolamide conjugates of the PG-J2 
or /∆12-PG-J
2
. The table below summarizes the m/z of the CID fragments identified by LC-ESI-
MS-MS analysis of the ethanolamide conjugates. 
 As the m/z 358 was identified as one of the product ions in the CID spectrum of m/z 376, 
it was essential to investigate the source of this ion shown in the Figure 5.1.3 (B). One of the 
possibilities is that it could have been resulted from the fragmentation of m/z 376 during ion 
transmission in the LC-ESI-MS analysis. Another possibility is that it is 15-deoxy12,14 PG-J2 
and was synthesized by the cells. To investigate this, LC-ESI-MS-MS analysis of m/z 376 was 
done performed at the same low collision energy, 5 eV, which was the typical operating collision 
energy during an LC-ESI-MS analysis. The mass spectrum obtained was compared to the one 
obtained from an LC-ESI-MS analysis. The objective of the analysis was to compare the 
intensities of the parent ion (m/z 376) and the product ion (m/z 358) with their corresponding 
intensities shown in the mass spectrum obtained by LC-ESI-MS analysis (Figure 5.1.5 B). 
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Figure 5.1.5 A) LC-ESI-MS/MS mass analysis of the parent ion (m/z 376) at collision energy 
5eV B) LC-ESI-MS analysis of AEA treated sample at collision energy 5eV. 
 Figure 5.1.5A illustrates that the product ion (m/z 358) occurs to a limited extent at 5 eV 
collision energy (~15% relative intensity). On the other hand the mass spectrum obtained during 
an LC-ESI-MS analysis (Figure 5.1.5 B) demonstrates that the signal intensity of the m/z 358 is 
three fold higher the intensity of m/z 376. The high intensity of m/z 358 in the mass spectrum 
could not have been formed by CID of m/z 376 in the mass spectrometer  Thus, the majority of 
signal from m/z 358 corresponds to 15-deoxy12, 14PG-J2 that was synthesized by the cells. 
Summarizing all the above data it can be concluded that AEA gets metabolized to both 
15-deoxy12, 14 PG-J2   ethanolamide and 12 PG-J2/PG-J2 ethanolamide by the JWF-2 cells. 
Besides the J-series ethanolamide prostglandins, the PGE2-EA/PGD2-EA and PGF2α-EA were 
A 
B 
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identified at m/z 394 and 396 respectively. However, MS/MS studies were not carried out for 
further confirmation.   
5.2 Analysis of the effect of increasing dose of AEA on the production of the ethanolamide 
J-series PGs by LC-ESI-MS. 
 The goal of this experiment was to study the effect of increasing concentrations of AEA 
on the production of the ethanolamide J-series prostaglandins by the JWF-2 cells. As we did not 
use an internal standard in this experiment we were not able to quantify the ethanolamide J-series 
prostaglandins but we saw a reproducible pattern of how the dose of AEA affected the 
production of these prostaglandins. 
 On the day of experiment, cells were treated with 10, 20 and 30µM AEA or ethanol for 5 
hours followed by extraction and concentration. The samples were analyzed using LC-ESI-MS. 
To monitor the intensity of the prostaglandin-related peaks in the LC-MS data, extracted ion 
chromatograms of m/z 358 and 376 were generated.  Figure 5.2.1 shows these plots for m/z 358 
for the control and for cells dosed with 10, 20, and 30µM AEA. The plots are normalized against 
the highest signal intensity of m/z 358 which was observed in the 30μM AEA-treated sample, to 
illustrate the increase in the signal intensity of m/z 358 with increasing AEA dosage. 
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Figure 5.2.1: Normalized extracted ion chromatograms of AEA-treated samples showing the 
effect of increasing concentration of AEA on the levels of 15-deoxy ∆12,14 PG-J2 
ethanolamide(m/z 358)  
 The chromatograms indicate a direct correlation between the intensity of the molecular 
ion(m/z 358) of 15-deoxy ∆12,14 PG-J2  ethanolamide and the dose of AEA. The experiment was 
done in duplicates and the same pattern was observed for the intensity of ethanolamide-
conjugated 15-deoxy ∆12, 14 PG-J2 and 12 PG-J2/PG-J2.  The statistics will be shown later in 
chapter 6. 
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Figure 5.2.2 LC-ESI-MS analysis of A) 10µM B) 30µM AEA treated sample. The number on 
the top is the m/z of the depronated molecule of the ethanolamide J-series prostaglandins and the 
number below the m/z indicates the absolute intensity of the molecular ion. 
 
 The mass spectra obtained by scanning the chromatographic peak eluting at  
0.5-3.0 minutes from LC shown in Figure 5.2.2 demonstrates the effect of an increasing dose of 
AEA treatment. The spectrum shows the relative and absolute intensities of both the 
ethanolamide J-series prostaglandins. It was observed that absolute intensity of the ethanolamide 
conjugates of the J-series increased with increase in the dose of AEA. Hence, the ethanolamide 
J-series prostaglandins were found to be produced in a dose-dependent manner. 
 
15-deoxy ∆12,14 PG-J2 Ethanolamide
PG-J2/ ∆12,14 PG-J2 Ethanolamide
15-deoxy ∆12,14 PG-J2 Ethanolamide
PG-J2/ ∆12,14 PG-J2 Ethanolamide
358.3
3862
358.3
9932
358.3
3862
358.3
9932
376.3
2641
A 
B 
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5.3 Analysis of the N-acetyl cysteine conjugates of ethanolamide J-series PGs by 
 LC-ESI-MS 
N-acetyl cysteine(NAC) is an antioxidant that is known to minimize oxidative stress inside 
the cells similar to that of the glutathione. It was reported that by pretreating the cells with N-
acetyl cytsteine followed by treatment with AEA or ethanol, the apoptosis induced by AEA was 
minimized6. The objective of this experiment was to investigate the mechanism by which NAC 
effects AEA induced apoptosis and determine if it was related to the production of NAC 
conjugates of the ethanolamide prostaglandins. This was achieved by subjecting the treated 
media for the by LC-ESI-MS analysis. The cells were treated as follows: 
a) Water (pretreatment) and Ethanol(treatment)  
b) NAC (pretreatment) and Ethanol(treatment) 
c) Water (pretreatment) and AEA(treatment) 
d) NAC (pretreatment) and AEA(treatment) 
The treatments (a) and (b) are the controls used to monitor apoptosis by either the solvents or the 
NAC. 
Table 5.3 Possible Mass spectral fingerprints of the NAC conjugates of the ethanolamide 
 J-series prostaglandins 
Molecule (M+EA-H)¯ (M+EA+NAC-H)¯ 
PG-J2 376.2 539.3 
15-deoxy- 
∆12,14-PG-J
2
 
358.2 521.3 
∆12-PG-J
2
 376.2 539.3 
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 Table 5.3 lists the possible m/z ratios of the NAC conjugates of the ethanolamide 
conjugates. Spectra were obtained by averaging the scans across the chromatographic peak 
eluting around 0.5-3.0minutes from LC. The mass spectrum shows a peak at m/z 539 
corresponding to the NAC conjugate of the 12 PG-J2/PG-J2 ethanolamide (Figure 5.3.1 B). The 
peak identified as NAC conjugate of 12 PG-J2/PG-J2 ethanolamide was subjected to 
 LC-ESI-MS-MS analysis to obtain more specific structural information. This was essential to 
confirm the identity of the peak as the deprotonated molecule of the NAC conjugate of 12 PG-
J2/PG-J2 ethanolamide. 
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Figure 5.3.1 The LC-ESI-MS analysis of A) NAC and ethanol treated B) NAC and AEA 
treated samples. 
 The following is the CID spectrum (Figure 5.3.2) obtained for the parent ion  
(m/z 539) by scanning across the chromatographic peak eluting around 0.5-3.0 minutes. While 
the largest intensity product ion, m/z 162, is the deprotonated molecule of NAC, the spectrum 
shows product ions which are identified as prostaglandin-related peaks, such as m/z 358 and 271. 
Hence, the NAC conjugate of 12 PG-J2/PG-J2 ethanolamide has been identified and confirmed. 
The NAC conjugate of the 15-deoxy ∆12, 14 PG-J2 ethanolamide was identified at m/z 520 in the 
mass spectra scanned across the chromatographic peak eluting at 4.0-5.0 minutes. However, the 
A 
B 
(M+EA+NAC‐H)¯ 
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LC-ESI-MS-MS analysis of the parent ion peak did not yield product ion peaks that could be 
attributed to 15-deoxy ∆12, 14 PG-J2 ethanolamide.  Hence, m/z 520 was not confirmed as a NAC 
conjugate of15-deoxy ∆12, 14 PG-J2 ethanolamide. 
 
                  
Figure 5.3.2 The LC-ESI-MS-MS analysis of the parent ion (m/z 539) of   
NAC and AEA treated samples. 
5.4 .Analysis of the effect of COX-2 inhibition on production of the ethanolamide J-series 
PGs by LC-ESI-MS experiments 
 As mentioned in Chapter 1.3.1, the enzyme COX-2 plays a very important role in the 
metabolism of AEA to the pro-apoptotic ethanolamide J-series prostaglandins. The goal of this 
experiment was to investigate the role of the enzyme COX-2 in the production of the 
ethanolamide conjugates of the J-series prostaglandins by inhibiting this enzyme with a COX-2 
inhibitor. A commercially available COX-2 inhibitor is NS-398. 
 The treatment was done as follows: 
a) DMSO pretreatment and Ethanol treatment 
b) NS-398(25uM) pretreatment and Ethanol treatment 
 
(NAC-H)¯ 
(M+EA+NAC‐H)¯ 
(M+EA‐H‐H2O)¯ (M‐H‐H2O‐CO2)¯ 
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c) NS-398(50uM) pretreatment and Ethanol treatment 
d) DMSO  pretreatment  and AEA treatment 
e) NS-398(25uM) pretreatment and AEA treatment 
f) NS-398(50uM) pretreatment and AEA treatment 
 The treatments a, b and c were the controls used to monitor cell death induced by the 
inhibitor or the solvent. It was observed that the either the inhibitor or the solvent by itself did 
not induce any cell death. The mass spectrum obtained by the LC-ESI-MS analysis for treatment 
(d) showed a peak at m/z 358 and 376(data not shown), corresponding to the ethanolamide 
conjugates of the J-series prostaglandins. Alternately, the mass spectra obtained for the treatment 
(e) and (f) by the LC-ESI-MS analysis did not show any peaks related to the ethanolamide 
conjugates of the J-series prostaglandins. This indicates that, when COX-2 was blocked by a 
selective COX-2 inhibitor, the AEA was not metabolized to the ethanolamide prostaglandins. 
Hence, COX-2 is required for the production of ethanolamide conjugates of J-series 
prostaglandins. The experiment was done in duplicate and the data is found to be reproducible. 
The statistics will be discussed in Chapter 6. 
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Chapter 6: Results and Conclusions 
6.1   AEA is metabolized to ethanolamide conjugates of J-series prostaglandins 
 Although it has been reported that AEA is metabolized to J-series prostaglandins by  
Van Dross, et al6, the pathway of its metabolism was uncertain. To investigate the pathway, the 
samples were analyzed using LC-ESI-MS. Mass spectrometry can distinguish between the 
possible prostaglandins based on the m/z ratios of the ions, and MS/MS spectra can be used to 
verify the identity of the prostaglandins.   
 It was found that when JWF2 cells are treated with AEA, the cells metabolize AEA to 
ethanolamide conjugates of the J-series prostaglandins in the presence of the enzyme COX-2, as 
illustrated in the Figure 5.1.3(B).  This enzyme plays a key role in metabolizing AEA to 
cytotoxic ethanolamide J-series prostaglandins which selectively induce apoptosis in tumor cells.  
The presence of the ethanolamide conjugates of the E-,F- and D-series and the absence of the 
unconjugated J-series prostaglandins confirms that AEA is metabolized to ethanolamide 
prostaglandins in pathway B, shown in Figure 6.1. Thus, AEA-induced cytotoxicity in tumor 
cells is mediated by the production of ethanolamide conjugates of J-series prostaglandins. This is 
the first time the production of ethanolamides of J-series prostaglandins has been reported. 
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Figure 6.1 AEA is metabolized by COX-2 followed by prostaglandin synthase D to D-series 
ethanolamide prostaglandins, which undergoes dehydration to ethanolamide conjugates of J-
series prostaglandins 
6.2   AEA is metabolized to ethanolamide conjugates of J-series prostaglandin in a dose-
dependent manner 
 It was observed that with increasing concentration of AEA, the absolute mass spectral 
intensity of both the 12 PG-J2/PG-J2 (m/z 376) and 15-deoxy12,14 PG-J2 (m/z 358) ions 
increased.  Recall that m/z 358 is a possible product ion from m/z 376, but under the conditions 
used in a typical LC-ESI-MS experiment, the production of m/z 358 from m/z 376 is small.  
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Thus, the intensity of m/z 358 may be identified as 15-deoxy12,14 PG-J2 and monitored as direct 
evidence of the effects of increasing AEA dosage.  
 Figure 6.2 illustrates increase in mass spectral intensity of m/z 358 and 376 with 
increasing AEA dosage. Error bars represent standard deviations of two measurements.  The 
trend of increased prostaglandin production from increased AEA concentration is present in all 
experiments, but the standard deviations were large.  This may be because biological systems 
often fluctuate in terms of their growth and the physiological response to a drug.  The nature of 
response can be consistent but the extent of response may differ.  In addition, mass spectral 
intensity varies as a function of the efficiency of ionization, transmission, and detection, all of 
which may not be reproducible among experiments.  Hence, it can be concluded that AEA 
metabolizes to ethanolamide J-series prostaglandins in a concentration dependent manner. 
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Figure 6.2 Effect of increasing concentration of AEA on the relative intensity of ion 
(m/z 358) of 15-deoxy ∆12,14 PG-J2 ethanolamide (A), (m/z 376) of the 12 PG-J2/PG-J2 
ethanolamide (B). 
A 
B 
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6.3 N-acetyl cysteine conjugates with PG-J2 / ∆12 PG-J2 ethanolamide. 
 It was reported that when the cells were pretreated with NAC followed by AEA, that 
NAC inhibited AEA induced apoptosis6. As discussed earlier in Chapter 5.3, NAC was found to 
conjugate with the PG-J2 / ∆12 PG-J2 ethanolamide as illustrated in the Figure 5.3.2(B).It can be 
concluded that NAC inhibits AEA induced apoptosis by conjugating with PG-J2 / ∆12 PG-J2 
ethanolamide. 
6.4 Metabolism of AEA to Ethanolamide J-series Prostaglandins is inhibited by  
      NS- 398(COX-2 inhibitor)  
 NS-398 is a selective inhibitor of COX-2 which plays a key role in the metabolism of 
AEA to ethanolamide conjugates of J-series prostaglandins. It is observed that when the cells 
were pretreated with NS-398 followed by AEA, the production of the prostaglandins was 
inhibited.  Fig. 6.4.1 illustrates this by plotting the absolute signal intensity of the m/z 358 
against the treatment. 
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Figure 6.4.1 Effect of COX-2 inhibitor on the relative intensity of the molecular ion peak (m/z 
358) of 15-deoxy ∆12,14 PG-J2  ethanolamide 
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Figure 6.4.2 Effect of COX-2 inhibitor on the relative intensity of the molecular ion peak (m/z 
376) of PG-J2 / ∆12 PG-J2 ethanolamide. 
 These results indicate that when the enzyme COX-2 is inhibited, AEA does not get 
metabolized to ethanolamide prostaglandins of J-series. Hence, AEA gets metabolized to 
ethanolamide conjugates of J-series prostaglandins in COX-2 dependent manner. 
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Chapter 7: Future Work 
 
7.1 Quantification of the ethanolamide J-series Prostaglandins 
Although we could identify the AEA metabolites as ethanolamide conjugates of the  
J-series prostaglandins, quantifying them using either ELISA or LC-ESI-MS is still a big 
challenge. As the conjugates are not available commercially, a calibration curve cannot be 
generated by either technique for quantification. Custom ethanolamide derivatives can be 
synthesized from the related carboxylic acid and amine compounds using standard coupling 
reagents in the laboratory of colleague Dr. Colin Burns in the Department of Chemistry at ECU.   
This synthesis was attempted in 2010, but only very small volumes of reactants were available 
which evaporated very quickly before mixing and reacting.  If future attempts are successful, the 
synthesized ethanolamide conjugates along with a deuterated internal standard to monitor 
chromatographic performance can be used to quantify ethanolamide conjugates with  
LC-ESI-MS19,20. 
7.2 Investigation of the intracellular levels of ethanolamide J-series Prostaglandins  
The ethanolamide conjugates of the J-series prostaglandins released into the media were 
extracted and analyzed successfully by LC-ESI-MS. But, the actual amount of these 
ethanolamide conjugates synthesized by the cells and the extent to which they are released into 
the media is not known. This can be studied by extracting the cells for prostaglandins followed 
by LC-ESI-MS analysis. For analyzing the intracellular levels of ethanolamide conjugates, 
developing an efficient extraction protocol would be the most challenging part because of the 
interfering cellular matrix. Although difficult, if the intracellular levels of these prostaglandins 
are determined it would really help understand the mechanism of action of AEA more clearly. 
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7.3 Investigation of the production of  glutathione conjugates of the ethanolamide  
J-series prostaglandins 
Many studies have reported that when J-series prostaglandins are incubated with 
Glutathione under physiological conditions21,22, it resulted in the formation of glutathione 
conjugates of the J-series prostaglandins. Also, Murphey, et al, have demonstrated that when 
breast cancer cells were treated with15-deoxy ∆12, 14 PG-J2, the glutathione conjugate of 15-
deoxy ∆12,14 PG-J2  was produced by the intact cells. Hence, the formation of glutathione 
conjugates of the J-series prostaglandins has been reported both in vivo and vitro. The 
ethanolamide conjugates of J-series prostaglandins also have an α, β-unsaturated carbonyl 
moiety that can readily conjugate with the thiol groups on glutathione similar to the unmodified 
J-series prostaglandins. Thus, the production of glutathione conjugates of the ethanolamide J-
series prostaglandins can also be investigated similarly by incubating the cells with AEA and 
glutathione under physiological conditions.  The cells after incubation can be extracted for the 
glutathione conjugates of the ethanolamide prostaglandins followed by LC-ESI-MS analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
57 
 
 
References 
1. PubMed Health.  Medical encyclopedia. Last reviewed August 14, 2010. Available at: 
http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002267/ 
2. American Cancer society. Last reviewed March 21, 2012. Available at: 
http://www.cancer.org/Cancer/CancerBasics/what-is-cancer 
3. Skin Cancer Foundation. Skin Cancer Facts. Skin cancer Foundation. Available at: 
http://www.skincancer.org/skin-cancer-information 
4. Camp, L.W.; Turham, W. J.; Athar, M.; Elments, A.C. (2011).  New agents for 
prevention of Ultraviolet Induced Non-melanoma Skin Cancer.  Semin Cutan Med Surg. 
Elsevier, 30, 6-13. 
5. MedicineNet.com. Available at:  http://www.medicinenet.com/skin_cancer/article.htm 
6. Kuc,C.; Jenkins, A.; Van Dross, R.T. (2012).  Arachidonoyl Ethanolamide (AEA)-
Induced Apoptosis is Mediated by J-Series Prostaglandins and is Enhanced by Fatty Acid 
Amide Hydrolase (FAAH) Blockade.  Molecular Carcinogenesis, 51, 139-149.  
7. Manuel, G. (2008). Cannabinoids: Potential anticancer agents.  NATURE REVIEWS, 3, 
745-755. 
8. Siegmund, S.V.; Seki, E.; Osawa, Y. Uchinami, H.; Cravatt, B.F. Schwabe, R.F.  (2006).  
Fatty Acid Amide Hydrolase Determines Anandamide-induced Cell Death in the Liver.  
J. Biol. Chem.  281, 10431-10438. 
9. Cozzolino, R.; Cali, G.; Bifulco, M.; Laccetti, P. (2010). A metabolically stable analogue 
of anandamide, Met-F-AEA, inhibits human thyroid carcinoma cell lines by activation of 
apoptosis. Springer Link 28, 115-123. 
10. Laezza, C.; Pisanta, S.; Crescanzi, E.; Bifulco, M. (2006). Anandamide inhibits Cdk2 and 
activates Chk1 leading to cell cycle arrest in human breast cancer cells. Elsevier, 580, 
6076-6082. 
11. Van Dross, R. T.  (2009). Metabolism of Anandamide by COX-2 Is Necessary for 
Endocannabinoid-Induced Cell Death in Tumorigenic Keratinocytes.  Molecular 
Carcinogenesis.  48, 724-732. 
12. Weber, A.; Ni, J.; Ling, K.-H. J.; Acheampong, A.; Tang-Liu, D. D.-S.; Burk, R.; 
Cravatt, B.F.; Woodward, D.  (2004).  Formation of prostamides from anandamide in 
FAAH knockout mice analyzed by HPLC with tandem mass spectrometry.  J. Lipid. Res.  
45, 757-763. 
13. Kozak, K.R.; Crews, B.C.; Morrow, J.D.  (2002).  Metabolism of the endocannabinoids, 
2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and 
prostacyclin glycerol esters and ethanolamides.  J. Biol. Chem.  277, 44877-44885. 
 
 
58 
 
14. Yu, M.; Ives, D.; Ramesha, C.S.  (1997).  Synthesis of prostaglandin E2 ethanolamide 
from anandamide by cyclooxygenase-2.  J. Biol. Chem.  272, 21181-21186. 
15. William, F. Stenson. (1999). Current protocols in Immunology. Immunologic studies in 
Humans, 7.33.1-7.33.16. 
16. Daniel, C. Harris. Mass spectrometry. Quantitative Chemical Analysis, Seventh edition, 
488. 
17. Chernushevich, V.I.; Loboda, V.A.; Thomson, A.B. (2001). An introduction to the 
quadrupole-ion-trap-mass spectrometry.  J. Mass Spectrom. 36, 849-865. 
18. Murphy, R.C.; Barkley, R.M.; Berry, K.Z.; Hankin, J.; Harrison, K.; Johnson, C.; Krank, 
J.; McAnoy, A.; Uhlson, C.; Zarini, S.  (2005).  Electrospray ionization and tandem mass 
spectrometry of eicosanoids.  Anal. Biochem.  346, 1-42. 
19. Margalit, A.; Duffin, K.L.; Isakson, P.C.  (1996).  Rapid Quantitation of a Large Scope of 
Eicosanoids in Two Models of Inflammation:  Development of an Electrospray and 
Tandem Mass Spectrometry Method and Application to Biological Studies.  Anal. 
Biochem.  235, 73-81. 
20. Yang, P.; Felix, E.; Madden, T.; Fischer, S.M.; Newman, R.A.  (2002).  Quantitative 
high-performance liquid chromatography/electrospray ionization tandem mass 
spectrometric analysis of 2- and 3-series prostaglandins in cultured tumor cells.  Anal. 
Biochem.  308, 168-177. 
21. Cox, B.; Murphey, L.J.; Zackert, W.E.; Chinery, R.; Graves-Deal, R.; Boutaud, O.; 
Oates, J.A.; Coffey, R.J.; Morrow, J.D.  (2002).  Human colorectal cancer cells 
efficiently conjugate the cyclopentenone prostaglandin, prostaglandin J2, to glutathione.  
Biochim. Biophys. Acta, 1584, 37-45. 
22. Hardy, K.D.; Cox, B.E.; Milne, G.L.; Yin, H.; Roberts, II, L.J.  (2011).  Nonenzymatic 
free radical-catalyzed generation of 15-deoxy-∆12,14-prostaglandin J2-like compounds 
(deoxy-J2-isoprostanes) in vivo.  J. Lipid Res. 52, 113-124. 
 
 
 
 
 
 
